↓ Skip to main content

Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy

Overview of attention for article published in BMC Cancer, May 2008
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

blogs
1 blog
video
2 YouTube creators

Citations

dimensions_citation
101 Dimensions

Readers on

mendeley
84 Mendeley
connotea
1 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy
Published in
BMC Cancer, May 2008
DOI 10.1186/1471-2407-8-132
Pubmed ID
Authors

John M Pendleton, Winston W Tan, Satoshi Anai, Myron Chang, Wei Hou, Kathleen T Shiverick, Charles J Rosser

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 4%
Australia 1 1%
Ukraine 1 1%
Tunisia 1 1%
Mauritius 1 1%
Canada 1 1%
Unknown 76 90%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 18%
Researcher 14 17%
Student > Ph. D. Student 11 13%
Other 7 8%
Student > Doctoral Student 3 4%
Other 15 18%
Unknown 19 23%
Readers by discipline Count As %
Medicine and Dentistry 24 29%
Agricultural and Biological Sciences 10 12%
Biochemistry, Genetics and Molecular Biology 7 8%
Nursing and Health Professions 5 6%
Chemistry 4 5%
Other 10 12%
Unknown 24 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 November 2020.
All research outputs
#5,886,672
of 23,877,203 outputs
Outputs from BMC Cancer
#1,432
of 8,503 outputs
Outputs of similar age
#22,625
of 80,117 outputs
Outputs of similar age from BMC Cancer
#6
of 20 outputs
Altmetric has tracked 23,877,203 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,503 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 80,117 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.